[go: up one dir, main page]

MX2009004615A - Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3). - Google Patents

Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3).

Info

Publication number
MX2009004615A
MX2009004615A MX2009004615A MX2009004615A MX2009004615A MX 2009004615 A MX2009004615 A MX 2009004615A MX 2009004615 A MX2009004615 A MX 2009004615A MX 2009004615 A MX2009004615 A MX 2009004615A MX 2009004615 A MX2009004615 A MX 2009004615A
Authority
MX
Mexico
Prior art keywords
ht2a
dopamine
receptors
hydroxitriptamine
eter
Prior art date
Application number
MX2009004615A
Other languages
English (en)
Inventor
Georg Jaeschke
Luca Claudio Gobbi
Rosa Maria Rodriguez Sarmiento
Lucinda Steward
Olivier Roche
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38962066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009004615(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009004615A publication Critical patent/MX2009004615A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a moduladores duales de los receptores de la serotonina 5-HT2A y de la dopamina D3 que se representan mediante la fórmula general I: (ver fórmula (I)) en la que R1, R2 y A tienen los significados definidos en la descripción, a un proceso para su obtención, a sus sales farmacéuticamente aceptables, destinados a la fabricación de medicamentos para el tratamiento o la prevención de trastornos cognitivos, adicción a las drogas, depresión, ansiedad, dependencia de las drogas, demencias, desequilibro de la memoria, trastornos psicóticos, incluida la esquizofrenia, trastornos esquizoafectivos, enfermedad bipolar, manías, depresión psicótica y psicosis que comprenden la paranoia y los delirios.
MX2009004615A 2006-10-31 2007-10-22 Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3). MX2009004615A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06123274 2006-10-31
PCT/EP2007/061253 WO2008052899A1 (en) 2006-10-31 2007-10-22 Ether derivatives dual modulators of the 5-ht2a and d3 receptors

Publications (1)

Publication Number Publication Date
MX2009004615A true MX2009004615A (es) 2009-05-22

Family

ID=38962066

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004615A MX2009004615A (es) 2006-10-31 2007-10-22 Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3).

Country Status (18)

Country Link
US (1) US7795437B2 (es)
EP (1) EP2079693B1 (es)
JP (1) JP5087631B2 (es)
KR (1) KR101114651B1 (es)
CN (1) CN101535258B (es)
AR (1) AR063438A1 (es)
AU (1) AU2007316249B2 (es)
BR (1) BRPI0718127A2 (es)
CA (1) CA2667511A1 (es)
CL (1) CL2007003110A1 (es)
ES (1) ES2401663T3 (es)
IL (1) IL198157A0 (es)
MX (1) MX2009004615A (es)
NO (1) NO20091675L (es)
PE (1) PE20081342A1 (es)
RU (1) RU2009116509A (es)
TW (1) TW200826940A (es)
WO (1) WO2008052899A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2480466C2 (ru) * 2007-07-26 2013-04-27 Ф.Хоффманн-Ля Рош Аг Двойные модуляторы 5-ht2a и d3-рецепторов
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2011060363A2 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
US8877778B2 (en) 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
US8722683B2 (en) * 2011-02-17 2014-05-13 Hoffmann La-Roche Inc. Benzodioxole piperazine compounds
US8921397B2 (en) 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024264A (en) * 1974-08-15 1977-05-17 Ab Ferrosan Diphenylbutylpiperidines
GB1514718A (en) 1974-08-15 1978-06-21 Ferrosan Ab Diphenyl-butylpiperidines
JP2860689B2 (ja) 1990-03-14 1999-02-24 第一製薬株式会社 ピリミジン誘導体
US5229400A (en) 1990-10-05 1993-07-20 Ajinomoto Co., Inc. Piperidine compounds and their use as antiarrhythmic agents
SK11822001A3 (sk) 1999-03-26 2002-09-10 Astrazeneca Ab Modulátory chemokínovej aktivity, spôsoby ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie v terapii
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
WO2003048154A1 (en) 2001-12-04 2003-06-12 Actelion Pharmaceuticals Ltd 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
AU2003303678A1 (en) 2003-01-03 2004-08-10 Genzyme Corporation Urea derivatives and their use as anti-inflammatory agents
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CN101535258B (zh) 2012-12-05
CL2007003110A1 (es) 2008-06-13
KR101114651B1 (ko) 2012-06-12
BRPI0718127A2 (pt) 2014-02-18
AU2007316249B2 (en) 2013-01-24
CN101535258A (zh) 2009-09-16
RU2009116509A (ru) 2010-12-10
WO2008052899A1 (en) 2008-05-08
US20080103174A1 (en) 2008-05-01
ES2401663T3 (es) 2013-04-23
IL198157A0 (en) 2009-12-24
NO20091675L (no) 2009-05-28
AR063438A1 (es) 2009-01-28
TW200826940A (en) 2008-07-01
PE20081342A1 (es) 2008-09-18
AU2007316249A1 (en) 2008-05-08
JP5087631B2 (ja) 2012-12-05
US7795437B2 (en) 2010-09-14
EP2079693A1 (en) 2009-07-22
CA2667511A1 (en) 2008-05-08
KR20090075848A (ko) 2009-07-09
EP2079693B1 (en) 2013-02-27
JP2010508319A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
AR073622A1 (es) Compuestos de benzo[d]isoxazol moduladores de receptores de dopamina d3 y de la serotonina 5-ht2a, proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos psicoticos
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
UY31607A1 (es) Derivados bicíclicos de carboxamidas aza-bicíclicas, su preparación y su aplicación terapéutica
UY31606A1 (es) Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica
UY32391A (es) Compuestos amino-heterocíclicos
CR10541A (es) Formulas infantiles para el desarrollo temprano del cerebro
HN2012001413A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
PE20151788A1 (es) Inhibidores de bromodominios tetraciclicos
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
NI201100162A (es) Derivados de indol como antagonistas del receptor crth2
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
SV2009003411A (es) Compuestos de amino-heterociclico
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CO6361937A2 (es) Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa
UY32574A (es) Antagonistas del receptor cxcr3
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
CO6501188A2 (es) Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1
CO7280468A2 (es) Antagonistas del receptor de 5-ht3
UY30938A1 (es) Derivados de nicotinamida, sales y solvatos farmacéuticamente aceptables, composiciones y aplicaciones.
MX2009004615A (es) Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3).
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration